Torbjörn Bjerke (born 1962). President and CEO. MD.
Mr Bjerke joined the former Biolipox in 2003. Serves on the board of directors of NeuroSearch AS.
Held the position as President and CEO of Biolipox AB from 2004 to 2007. Previously, he has held Director of Research positions at AstraZeneca, and has served as Executive Vice President of R&D at ALK-Abello.
Shareholding and holding of options in Orexo AB: 108,108 shares and employee stock options entitling to 84.586 shares.
|
 |
Claes Wenthzel (born 1962). Executive Vice President & Chief Financial Officer. B.Sc. Bus. Adm.
Mr. Wenthzel joined Orexo in 2005. Chairman of the board of directors of Stille AB, and director of the board of directors of ProStrakan AB. Prior to joining Orexo Mr. Wenthzel has among other things served as Vice President and Chief Financial Officer of Perbio Science AB.
Shareholding and holding of options in Orexo AB: 10,000 shares and employee stock options entitling to 86,250 shares. |
 |
Thomas Lundqvist (born 1951). Executive Vice President & Head of Pharmaceutical Research & Development. M.Sc. Pharm.
Mr. Lundqvist is one of Orexo´s founders. He was director of the Company between 1995 and 2003 and its President between 1997 and 2002 and between December 2003 and April 2004. Mr Lundqvist has a long experience working with the development of new pharmaceuticals. Prior to joining Orexo, he held the position of President of NeoPharma Production AB. In addition, Mr. Lundqvist has more than ten years of experience working at the Swedish Medical Products Agency.
Shareholding and holding of options in Orexo AB: 495,250 shares and employee stock options entitling to 60,000 shares. |
 |
Charlotte Edenius (born 1958). Chief Scientific Officer and Head of Preclinical and Clinical Research & Development. MD, Ph.D.
Employed in former Biolipox since 2001.
Over 20 years of experience in inflammation research, particularly the area of arachidonic acid area and over approx. 15 years of experience in drug development. Most recently a senior position in Experimental Medicine at AstraZeneca.
Shareholding and holding of options in Orexo AB: 9,587 shares and employee stock options entitling to 54,902 shares. |
 |
Robin Wright (born 1964). SVP of Business & Commercial Development.
Prior to joining the company in June 2008, he held the position as Head of Corporate Advisory Services at BioScience Managers Limited. Robin Wright has extensive experience in corporate transactions and financial and strategic advice.
Shareholding and holding of options in Orexo AB: Employee stock options entitling to 50,000 shares. |
 |
Gunilla Ekström (born 1958). Senior Vice President of Project and Portfolio Management. PhD. MD.
Associate Prof. in Biochemical toxicology with 20 years experience of drug development, particularly the area of pain. Gunilla joined Orexo in November 2008.
Held since year 2000 the position of Global Product Director at Astra Zeneca with responsibility for pain projects portfolio. Member of the Therapeutic Area Neuroscience Management Group at AstraZeneca since 2005.
Shareholding and holding of options in Orexo AB: Employee stock options entitling to 40,000 shares. |
 |